We will rely on you to help lend your voice and support the biotechnology industry.
Bringing new treatments to patients, support public policies that promote innovation, improve patient access.
BIO International ConventionJune 3-6, 2019
BIO World Congress on Industrial Biotechnology and Ag TechJuly 8-11, 2019
BIO Industry Analysis Reports >>
Save. Advocate. Connect. Join Us.
A listing of all BIO members and subsidiaries.
February 11 - 12, 2019 | New York, New York
CONCARLO Holdings, LLC (Concarlo) is a precision medicine oncology company developing targeted solutions to diagnose and treat metastatic solid tumor cancers.
Experienced team with four decades of biotechnology and commercialization experience. Robust IP portfolio. Seeking to raise $7 MM in 2 trenches to fund IND-enabling studies, reach FIH Phase I & complete a corporate partnership.
Approximately 37,000 U.S. women will be diagnosed with metastatic ER/PR+, Her2- breast cancer this year, and despite recent advances, the median survival for these patients remains at ~2–3 y. Concarlo is developing a new class of drugs as well as a complementary diagnostic that target p27, a key on-off switch in many metastatic tumor types. Concarlo's therapeutics exhibit more potency against sensitive and resistant tumor types in vivo than CDK4 inhibitors, which are currently first-line therapy for metastatic breast cancer patients.